



## Capabilities Overview

**putting a face on the facts.**



AldenMC is a marketing communications agency mainly focused on branding Life Science, Biotech, Medical Device companies, and more. From messaging and positioning to corporate identity, websites, presentations, and collateral, Alden defines, nurtures, and activates corporate brands to bring their complex science to life. The goal is to help companies effectively connect with their multiple audiences and put a “Face on the Facts”.

### **Naming & Storytelling**

- *Naming Proposal*
- *Domain Research*
- *Concept Creation*
- *Narrative Architecture*
- *Copy Development*
- *Tagline / Headline*

### **Visual Identity**

- *Logotype Systems*
- *Typography Pairings*
- *Color Pairings*
- *Iconography*
- *Graphic Standards Manual*

### **Brand Collateral**

- *Print Materials*
- *Presentation Decks*
- *Stationery*
- *Social Media Toolkits*
- *Trade Show Collateral*

### **Web & Digital Design**

- *Website*
- *2D/3D Illustrations*
- *Motion Design*
- *Digital Experiences*
- *Webcare*

***we define, nurture & activate your unique brand***



Ligand

**Link**  
Cell Therapies

 **LONGBOARD**  
PHARMACEUTICALS

**LYCIA**  
THERAPEUTICS

**Melinta**  
THERAPEUTICS  
The Antibiotics Company

**Mersana**  
THERAPEUTICS

microrite

 **MLAB**  
BIOSCIENCES

**NALO**  
THERAPEUTICS

**NEW STREET**  
INVESTOR RELATIONS

 **NITRASE**  
THERAPEUTICS

**nurix**

 **OKYO**  
PHARMA

 **OTONOMY**

**Penn**

 **Pfizer**

 **Prelude**  
THERAPEUTICS

**prosciento**  
ADVISE • ADVANCE • ACHIEVE

 **qualigen**

 **RayzeBio**

 **Recludix**  
Pharma

**REGULUS**

 **REZOLUTE**

**SALUBRITAS**  
THERAPEUTICS

 **SAMSARA**  
BIOCAPITAL

 **SAPIENCE**  
THERAPEUTICS

 **Satsuma**

 **SAVARA**

 **senomyx**

 **SHATTUCK**  
LABS

 **tknife**  
THERAPEUTICS

**TOURMALINE**


**TURNSTONE**  
BIOLOGICS

 **Ventus**  
THERAPEUTICS

**viracta**


**VIRSCIO**

# corporate identity





**website**



view full site



We've helped cure more than a million patients.

Watch what's next.

**Enanta Pharmaceuticals**  
Great Chemistry Cures

**Careers**

Join Us | Culture | Core Values | Testimonials | Benefits

**Join Us**

**Why Enanta?**

At Enanta, you'll find a group of individuals who are passionate about their careers and committed to the vision of transforming the lives of patients with curative therapies. Working at Enanta isn't just a job, it is an experience - the Enanta Experience - where you have the opportunity to learn from industry leaders with years of deep biopharma expertise. When you join Enanta you open the door to many opportunities in your career journey. We continually strive for positive employee engagement. In fact, approximately 10% of our employees have been here for 15+ years.

[View Open Positions](#)

**Culture**

While many people join Enanta for the professional opportunities, they quickly come to value the unique culture. Each day, employees are empowered to reach their full potential and to have fun while doing so. Our work policy blends the best parts of remote work and in-office collaboration. We believe it is important to create an environment that best supports your performance and well-being. The Enanta Experience goes beyond having cold brew coffee, great snacks and happy hours. It involves working with a group of people who truly care and are aware that for the company to be successful, everyone has to be fulfilled in their career. When you are part of the Enanta Experience, your work is noticed and rewarded, and the difference you make here matters.

**Staying Connected**

During the pandemic, we were seeking ways to continue employee connection, and one employee suggested the creation of a virtual book club. This program became known as READS. Employees from a wide variety of disciplines in the company chose their first book with the caveat that it was healthcare related. This inspired our CEO, Jay Lully to launch other ideas such as EATS, SNAPS, SPROUTS and JOGS.

**EATS** **SNAPS** **SPROUTS** **JOGS** **READS**

**Giving Back to the Community**

Whether it be assembling hygiene kits for the local food pantry or volunteering during Watertown's May Month of Service, Enanta employees are always eager to support worthy causes especially when they impact the Watertown area.

We are committed to supporting science, technology, engineering, and mathematics (STEM) education for our local students. For the past 10 years we have had Watertown High School students visit Enanta's labs for "Lunch and Learn" with our scientists, and we have offered internships. We also partner with the [Watertown Community Foundation](#) to provide yearly grants to the Watertown Public Schools in support of STEM-related curriculum.

**Core Values**

At Enanta, our core values were purposefully created with our corporate vision in mind: to transform the lives of patients with curative therapies. We strive to abide by these values on a daily basis, not only to transform patients' lives, but to foster a culture of collaboration and inclusion within our company.

- Curious** | We are imaginative and innovative in using science to invent therapeutics.
- Respectful** | We mutually respect each other through our words and actions.
- Empathetic** | We are passionate about developing cures for patients.
- Agile** | We learn and adapt quickly to change.
- Team-Oriented** | We work collaboratively in an inclusive environment to achieve common goals.
- Entrepreneurial** | We actively embrace challenges in pursuit of new opportunities.

**Testimonials**

Click the images below to learn what our employees are saying about Enanta!

**Jonathan Lloyd**  
Senior Associate Scientist, Biochemistry

**Brendan Lou**  
Chief Business Officer

**Colleen Berube**  
Senior Executive Assistant and Investor Relations Associate

**Josh Klaene**  
Senior Scientist, DMX

**Michael Rhodin**  
Associate Director, Biology

**Benefits**

Enanta offers a comprehensive benefits package. Click the icons below for more information.

view full site



News Contact

PIPELINE SCIENCE PATIENTS COMPANY CAREERS



**PRECISE BY DESIGN,  
CONQUERING DISEASE AT ITS CORE**



News Contact

PIPELINE SCIENCE PATIENTS COMPANY CAREERS

### Careers

## JOIN US AND MAKE A DIFFERENCE

Together, we are leading the next wave of RNA therapeutics to transform the lives of patients.

We are a team dedicated to advancing next-generation RNA therapeutics with the potential to disrupt the treatment paradigm for challenging diseases. Our success is driven by focus, innovation, collaboration and execution – underpinned by our unwavering commitment to creating life-altering therapeutics for patients.

### Mission Statement

At ADARx, our mission is to develop transformative RNA therapeutics for the most challenging human diseases. Through relentless innovation, we aim to achieve precise, deep, and durable targeting of critical disease drivers, expanding the horizon of treatment possibilities beyond the limits of traditional modalities.

### Core Values

- Relentless Innovation
- Unwavering Integrity
- Empowered Collaboration
- Patient-Centered Excellence
- Genuine Respect

### Culture


We are a diverse team that comes together to drive innovation. With the freedom to take bold risks and a commitment to scientific excellence, we aim to unlock breakthroughs that matter. We are inspired by the unlimited possibilities of RNA science and the patients who face debilitating diseases every day.

### Benefits

- 401(k) with Company Match
- Medical, Dental, Vision
- Flexible Spending Account
- Life Insurance
- Employee Assistance Program



view full site



**immuneeering** [Our Story](#) [Our Science](#) [Our Pipeline](#) [Patients](#) [Investors](#) [Careers](#)

[Overview](#) [Leadership](#) [Team](#) [Board of Directors](#) [Scientific Advisory Board](#) [In the News](#)

**We Began with A Mission:**

**To Keep Patients Alive and Help Them Thrive**

Immuneeering was established based on a shared singular vision: to help people with cancer live longer without compromising quality of life during treatment. That conviction became the foundation of Immuneeering. From the beginning, our mission has remained clear and unwavering: develop therapies that improve survival while preserving the quality of life that matters most to patients and their families.

**How Cancer Is Targeted: Deep Cyclic Inhibitors**

Traditional cancer therapies often aim for rapid tumor shrinkage, an approach that can trigger the tumor to adapt quickly, limiting the duration of clinical benefit. We asked a different question: What if cancer treatment could work with greater endurance and fewer trade-offs for patients?

That question led to Deep Cyclic inhibitors, a novel therapeutic approach shaped by the biology of resistance. Instead of constant pressure, Deep Cyclic inhibitors pulses at a frequency designed to stay ahead of tumor adaptation while supporting healthier signaling in normal cells, offering a fundamentally different way to target cancer.

[Explore our Science](#) [Pipeline](#)

**Commitment to Patients and Quality of Life**


We believe that cancer treatment should not require patients to choose between more time and the ability to live their lives fully. Our Deep Cyclic Inhibition platform is grounded in an approach that unites powerful science with respect for the body. Clinical data from our lead Deep Cyclic inhibitor, atebimetinib, further reinforces our belief that cancer treatment can be both effective and compatible with maintaining daily function and quality of life during treatment.

[Patient Focus](#)

**Platform. Many Cancers. Endless Potential.**

Because the MAPK pathway is activated in roughly half of all cancers, Deep Cyclic inhibitors have relevance across a broad spectrum of tumor types. Our lead Deep Cyclic inhibitor, atebimetinib, is currently being advanced in pancreatic cancer and lung cancer, with plans to further evaluate its potential in other MAPK-pathway cancers. As momentum builds, we will expand opportunities to bring this approach to more patients who would benefit from improved cancer therapy options.

[Visit Our Pipeline](#) [Learn About Clinical Trials](#)



**Our goal isn't just to improve cancer treatment. It's to redefine what patients can expect from it. We're designing therapies to respect the body, enhance quality of life, and enable people to live normal lives and feel like themselves throughout treatment. Ultimately, we aspire to neutralize cancer's ability to kill, transforming it into a disease that people can live with.**

Ben Zeev PhD, Co-Founder, President & CEO Immuneeering

**immuneeering** [Contact](#) [Follow Us](#) [Legal](#)

© Immuneeering 2025. All Rights Reserved.

**Contact**  
[info@immuneeering.com](mailto:info@immuneeering.com)


**Boston**  
 245 Main St, 2nd Floor  
 Cambridge, MA 02142

**New York**  
 407 Madison Ave  
 New York, NY 10017

**San Diego**  
 10860 Torrey Pines Road  
 San Diego, CA 92037

We are using cookies to give you the best experience on our website. You can find out more about which cookies we are using or switch them off in settings. [Accept](#)

view full site





ABOUT SERALUTINIB PATIENTS INVESTORS CAREERS & CULTURE

# Seralutinib

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with these rare diseases.

[Learn More](#)





ABOUT SERALUTINIB PATIENTS INVESTORS CAREERS & CULTURE

## Expanded Access to Investigational Medicines Prior to Regulatory Approval

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to provide access to our investigational therapies at the appropriate time and in the most clinically appropriate manner for patients.

Patients are at the center of our clinical programs designed to fully answer important scientific questions about the potential benefits and risks of our investigational drugs, and obtain regulatory approval.

Gossamer Bio may provide access to its investigational medicines outside of enrollment in clinical trials on a case-by-case basis. If you have questions about our programs or eligibility for our clinical trials, please feel free to [contact us](#).

**Contact Information:**  
Interested physicians may submit questions or requests regarding a patient's eligibility for one of Gossamer Bio's ongoing clinical trials by emailing [clinicaltrials@gossamerbio.com](mailto:clinicaltrials@gossamerbio.com).

**Request Procedure:**  
Patients interested in obtaining access to a Gossamer Bio investigational therapy must do so via their physician. A licensed physician who believes their patient may benefit from access to a Gossamer Bio investigational therapy should contact us through the contact information above to make the request on behalf of the patient.

**Anticipated Timing:**  
Gossamer Bio will acknowledge receipt of any questions or requests received from licensed physicians within ten (10) business days of receipt. Making a request does not guarantee the granting of access to an investigational drug by Gossamer Bio.

In the U.S., physicians may find additional information regarding expanded access to investigational therapies by visiting the U.S. Food and Drug Administration website [Expanded Access Information for Physicians](#).

Non-U.S. physicians must follow local laws and regulations appropriate for the country originating the request.

For information on Gossamer Bio's clinical trials, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).



USA: 375 Merryfield Row, Suite 100, San Diego, CA 92121  
Ireland: 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 W80

Follow Us:  


© Gossamer Bio | 2018 | Privacy Statement | Prospective Candidate Privacy Notice

view full site



**B SUPREME** Clinical Trial Locations About the Study Pevifoscorvir sodium FAQ [LEARN MORE](#)

# A Clinical Research Study for Chronic Hepatitis B



**B SUPREME** Clinical Trial Locations About the Study Pevifoscorvir sodium FAQ [LEARN MORE](#)

## A Clinical Research Study for Chronic Hepatitis B

Learn more about the B-SUPREME study for people with chronic HBV infection. [CLICK HERE](#)

### CLINICAL TRIAL LOCATIONS

Locations (57)

Information on this website is directed towards U.S. residents only.

United States	Map	Satellite
Aligos Investigational Site Chandler, Arizona, 85224 United States		
Aligos Investigational Site Coronado, California, 92118 United States		
Aligos Investigational Site Garden Grove, California, 92840 United States		

### ABOUT THE B-SUPREME STUDY

The B-SUPREME study is a clinical research study for people with chronic hepatitis B. We're testing a new investigational drug called pevifoscorvir sodium to see if it works and is safe.

#### ELIGIBILITY CRITERIA

People who have never taken a medication for chronic hepatitis B before or stopped taking their last hepatitis B medication or experimental treatment more than six months ago may be eligible to participate in the study.

CONDITION	AGE
Chronic HBV Infection	18-65

STATUS  
HBeAg+ or HBeAg-

This clinical study is looking at a new investigational drug, pevifoscorvir sodium, to see if it can lower the amount of hepatitis B virus in the blood compared with a standard treatment, tenofovir disoproxil fumarate (TDF). We will also be checking to see if the investigational drug is safe and how people tolerate it. In addition, we'll be measuring certain proteins in the blood that are markers of the hepatitis B infection.

To join the clinical study, specific requirements must be met. More details can also be found at [ClinicalTrials.gov](#).



#### ABOUT PEVIFOSCORVIR SODIUM

Pevifoscorvir sodium (also known as ALG-00084) is a new investigational drug we are developing. It's a pill taken once a day. We're testing whether it will attack the hepatitis B virus by targeting its outer shell and help prevent the virus from growing and spreading.


### Clinical Trial FAQ

 <h4>WHAT IS AN INVESTIGATIONAL DRUG?</h4> <p>An investigational drug is one that is currently being tested and is not approved for use by global regulatory agencies such as the U.S. Food and Drug Administration (FDA).</p>	 <h4>WHAT IS A CLINICAL RESEARCH STUDY?</h4> <p>A clinical study, or trial, is a type of medical research that looks at how potential medicines affect the participants. These participants are volunteers. Each medicine that is</p>	 <h4>WHAT IS INFORMED CONSENT?</h4> <p>Informed consent is a process that begins at the clinic (clinical site), where a study doctor or research staff will explain the purpose, procedures, potential risks and possible benefits of the clinical</p>
---	--	---


view full site



view full site



view full site




ENGAGEBIO platform leadership partnering careers contact

# Unleashing DNA medicines

over 100x the expression of traditional non-viral DNA

**Highly Potent** **Non-immunogenic** **Redosable** **Ready to Scale**



ENGAGEBIO platform leadership partnering careers contact

# Unleashing DNA medicines

Non-immunogenic Redosable Ready to Scale

Engage Bio has developed Tethosomes, a new class of non-viral genetic medicine which finally unleashes potent, durable, redosable, and scalable genetic medicine.


Tethosome platform solves the two key hurdles that have held back the field of DNA: potency and toxicity. Using proven LNP technology, we deliver a specific DNA and an mRNA encoding our proprietary Tethosome protein. This localizes DNA to the nucleus, increasing expression by over 100-fold. Critically, our platform is invisible to immune sensors which detect foreign DNA and cause lethal immune reactions. This allows us to safely deliver potent DNA, when needed, and titrate expression to optimal levels.

**PARTNERING**

Engage is proud of our team of innovators and scientists dedicated to advancing new technologies with the potential to eliminate human diseases.

Engage is committed to leveraging the wide applicability of our Tethosome platform through external partnerships. We are actively seeking collaborations in areas ranging from gene replacement, oncology, and durable therapeutic protein expression. Our ideal partners share our vision to expand the boundaries of genetic medicine and to generate innovative medicines that improve human health.

# corporate deck





**SAVARA**  
Developing new therapies for rare respiratory diseases

**Corporate Overview**

## Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

*Overview and Burden of Disease*



### MOLBREEVI: U.S. Commercial Opportunity

**MOLBREEVI**

- Clinically meaningful benefit
- Strong stakeholder interest
- Orphan drug pricing potential
- Chronic dosing

**Long Term Exclusivity**

- 12-year biologic exclusivity (U.S.)
- Biosimilar competition unlikely

**Significant Unmet Need**

- High disease burden
- No FDA approved therapies
- Whole lung lavage is invasive and not standardized



**Significant Commercial Opportunity**

**Efficient Rare Disease Model**

- Small customer facing footprint
- Exclusive pharmacy network

© Savara Inc. All Rights Reserved. 42

# ALIGOS THERAPEUTICS

## CORPORATE PRESENTATION



### MASH


- Epidemiology, Pathogenesis
- Competitive Landscape

**ALIGOS**  
THERAPEUTICS

### MASLD/MASH

Global Disease with Limited Treatment Options

66B people worldwide living with MASLD/MASH; the highest prevalence in East Asia/Asia Pacific and South Asia. Global prevalence is 30% and a leading cause of liver-related morbidity including cirrhosis, hepatocellular carcinoma, liver transplant, and end-stage liver disease



Region	Prevalence
North America	114M
Europe	112M
Middle East/North Africa	162M
East Asia & Asia Pacific	421M
South-East Asia	109M

**ALIGOS**  
THERAPEUTICS

Hepatology, 2023 Apr; 77(4): 1335-1347.

6



**Adcentrx**  
THERAPEUTICS

## Company and Technology Overview



### Accelerated Breakthroughs

#### Innovative ADC Technology

- Stable i-Conjugation™ with cleavable linker
- Auristatin payload with 10x higher tolerability than MMAE
- DAR8 well-positioned for solid tumors



#### Pipeline Of Differentiated ADCs

- Phase 1 Nectin-4 ADC with 6x wider TI than MMAE ADC
- Broad pipeline of ADC assets with first-in-class potential



#### Company Poised For Success

- Top-tier investors
- Seasoned management team
- Matching best technology with the right tumor targets





**SENTI BIO**

## Engineering the Future of Cell and Gene Therapies

SENTI-202 : Clinical Strategy and Objectives




**SENTI BIO**

## SENTI-202

Designed to Address AML Heterogeneity Which Contributes to Disease Relapse/Refractoriness

## AML is an Aggressive Cancer with High Unmet Need Despite Recent Approvals



**1960** Chemotherapy first introduced for AML in 1960s

**1970** Cytarabine + anthracycline regimens (3+7) become standard of care for AML in 1970s

**1980** Allogeneic stem cell transplantation shows OS advantage in younger AML pts

**2000** Gemtuzumab approved for R/R AML but withdrawn in 2010 owing to toxicities

**2010** CPX-351 for untreated t-AML or AML-MRC  
 Gemtuzumab + azacitidine +/- induction for CD33+ AML  
 VEN+LDAC/HMA for untreated AML (older or unfit)  
 Glasdegib + LDAC for untreated AML (older or unfit)  
 Midostaurin plus induction/consolidation chemo for newly diagnosed FLT3-mut AML  
 Gilteritinib for R/R FLT3-mut AML  
 Ivosidenib for R/R IDH1-mut AML  
 Enasidenib for R/R IDH2-mut AML

**2012** Decitabine approved for older patients with AML


**2015** Azacitidine approved for older patients with AML >30% blasts





**2020** Personalized cancer therapy



**SENTI BIO**





7


# animation and video















**illustration/moa**










**print collateral**







**AIRFLOW VISUALIZATION**

Airflow visualization, often called “smoke studies,” is a critical technique used to assess how air moves within a cleanroom. By releasing visible, noncontaminating tracer particles, the airflow patterns around equipment, workstations, and personnel can be observed in real time. This allows engineers and quality professionals to confirm that the cleanroom’s air handling system effectively protects products and processes by sweeping away contaminants and maintaining unidirectional flow where required.



**WHY IT MATTERS**

In regulated environments such as pharmaceutical, biotechnology, and medical device manufacturing, uncontrolled airflow can lead to product contamination and regulatory non-compliance. Airflow visualization helps identify adverse airflow patterns such as turbulence, dead spaces, or other air patterns that can act as a channel or reservoir for contamination. These insights support risk assessments, guide equipment placement, and provide documented evidence to regulators that the cleanroom is functioning as designed.

**WHY PEOPLE NEED IT**

**REGULATORY COMPLIANCE**

The FDA, EMA, PIC/S, and WHO require airflow visualization studies as part of qualification and ongoing monitoring.

**PRODUCT SAFETY**

Ensures that airborne contaminants do not compromise sterile products or sensitive processes.

**OPERATIONAL EFFICIENCY**

Identifies potential design or procedural issues early, reducing costly deviations or contamination events.

**TRAINING TOOL**

Visualization serves as a powerful way to educate operators about cleanroom behaviors and reinforce good aseptic practices.

[www.microrite.com](http://www.microrite.com)  
[www.tracerparticlegenerator.com](http://www.tracerparticlegenerator.com)  
[Info@microrite.com](mailto:Info@microrite.com)  
[support@microrite.com](mailto:support@microrite.com)


[www.microrite.com](http://www.microrite.com)

flyer



business card

# Fluorochrome Performance Guide



## Prioritize clean fluorochromes and simplify panel design

Flow cytometry users choose from hundreds of fluorochromes for their conventional and spectral flow cytometry assays. The physical properties of all fluorochromes are not the same, and differences in resolution and spillover can significantly impact panel resolution and data interpretation. The process of learning every fluorochrome's properties can seem overwhelming and intimidating. As a result, flow cytometry users feel more comfortable using familiar fluorochromes, such as PerCP-Cy5.5 or PE tandems, which may present challenges and even limit or compromise the quality of data.

This guide is intended to help simplify panel design and minimize loss of data quality and resolution. By using the Fluorochrome Performance Chart and the Fluorochrome and Antigen Pairing Guide presented here, you can easily prioritize fluorochromes with minimal spillover and appropriate resolution.

### Fluorochrome Performance Chart

Resolution (SI)	4	BV421 BB515 RB744 RB780 RY586	RB613 RB670 RB705 PE RY703	RY743 RY775 PE-Cy7 RR688	BV711 BB700 PE-CF594 RY655	BV650 PE-Cy5
	3	BB824 RY610 Alexa Fluor™ 647 R718	BUV615 BV480 BV786 APC APC-R700		BUV563 BUV737 BV605	BUV661
	2	BUV395 RV828 FITC RB545	BUV496 BV510 BV750		BV570	PerCP-Cy5.5
	1	BUV805 V450 V500 Alexa Fluor™ 488 Alexa Fluor™ 700	APC-Cy7 APC-H7			PerCP
		1	2	3	4	
		Spillover				

Chart contains representative fluorochromes compatible with a 5-laser spectral flow cytometer. Table may differ based on instrument configuration and settings. Spillover ranking is based on cross-laser excitation and does not take into account spillover into adjacent detectors.



flyer

## Metabolic Pathways and the Immune System




Image was adapted from Ahl P, Hopkins RA, Xiang WW, et al. Met-Flow, a strategy for single-cell metabolic analysis highlights dynamic changes in immune subpopulations. *Commun Biol*. 2020;3(1):305. doi: 10.1038/s42003-020-1027-9

[bdbiosciences.com/metflowabs](https://bdbiosciences.com/metflowabs)


For Research Use Only. Not for use in diagnostic or therapeutic procedures.

BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2024 BD. All rights reserved. BD-124316 (v1.0) 0424



poster

# conference







**Minimize spillover,  
Maximize breakthroughs.**  
BD Horizon RealYellow™ and  
BD Horizon RealBlue™ Reagents

Ambiguous flow cytometry results can hinder your research, which is why we're engineering new fluorochromes for the blue and yellow-green lasers. Maximize your panels for both conventional and spectral flow cytometry with the growing family of BD Horizon RealYellow™ and BD Horizon RealBlue™ Reagents. Explore the hundreds of specificities available to help improve data resolution and enable new biological discoveries.

Make your mark. Discover how at [bdbiosciences.com/real](http://bdbiosciences.com/real)



For Research Use Only. Not for use in diagnostic or therapeutic procedures.  
BD, the BD Logo, BD Horizon RealBlue and BD Horizon RealYellow are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved. BD-111553 (v1.0) 1223




[bdbiosciences.com/real](http://bdbiosciences.com/real) 

**Minimize spillover,  
Maximize breakthroughs.**  
BD Horizon RealYellow™ and  
BD Horizon RealBlue™ Reagents  
Discover how at [bdbiosciences.com/real](http://bdbiosciences.com/real)

To us, design is not just what meets the eye,  
**but what awakens the brain.**



**Lesley Guilmette**  
*President*



**Maxwell Sherman**  
*Partner | Creative Director*

Wherever you are in your company's journey, look to  
Alden as your creative partner.

 reach **out**

619.544.9299

[contact@aldenmc.com](mailto:contact@aldenmc.com)

 come **visit**

1495 Pacific Hwy. Suite 250  
San Diego, CA 92101

**putting a face on the facts.**